Radiotherapy Market by Product, Type, Procedure, Application, End-User

List of Tables

[196 Pages Report] The Radiotherapy Market size was estimated at USD 6.64 billion in 2023 and expected to reach USD 7.03 billion in 2024, at a CAGR 6.04% to reach USD 10.01 billion by 2030.

Radiotherapy comprises businesses in the medical and healthcare sectors that harness radiation as a mode of treatment, typically for cancer and some non-malignant conditions. It involves deploying high-energy radiation, such as X-rays, gamma rays, and charged particles, primarily destroying cancerous cells, minimizing their growth, and reducing symptoms in palliative cases. The growing adoption of radiotherapy procedures for cancer treatment and rising preference for minimally invasive procedures influence the development of radiotherapy. In contrast, high treatment costs, limited availability of trained professionals, and risks associated with radiation exposure are restricting the utilization of radiotherapy. However, several vendors are working and investing in R&D to overcome these issues. Furthermore, technological advancements and improvements in radiotherapy devices and the introduction of robotic radiotherapy systems for cancer treatment are opportunities for businesses to create and market cutting-edge devices.

KEY MARKET STATISTICS
Base Year [2023]	USD 6.64 billion
Estimated Year [2024]	USD 7.03 billion
Forecast Year [2030]	USD 10.01 billion
CAGR (%)	6.04%

Product: Advancements in hardware manufacturing process as it provide high radiation doses to the tumor site

The hardware encapsulates all the tangible elements employed in administering radiotherapy treatment. These include linear accelerators, brachytherapy devices, proton therapy, and cyber knife systems. The software and service segment refers to the platforms used to plan treatment protocols, simulate radiation doses, and manage patient data and analytics. Services encompass various support functions, including equipment maintenance, training, technical support, and consulting. In comparison, the hardware provides the physical means to deliver treatment, while software & service ensure precise targeting, dose planning, and seamless operation.

Type: Consumer preference for external beam radiotherapy/teletherapy as they target tumor from outside and large tumors

External beam radiotherapy (EBRT)/ teletherapy is a common form of radiation treatment where the radiation originates outside the patient and is directed toward the cancer site. Conventional cobalt-60 teletherapy units provide continuously rotating radiation therapy for cancer treatment and are highly efficient with deeper penetration capabilities. Linear accelerators (LINACs) deliver high-energy X-rays to the patient's tumor region, damaging the cancerous cells' genetic material and disrupting their growth. Conventional linear accelerators utilize microwave technology to accelerate electrons before colliding them with a heavy metal target, thus generating high-energy X-rays. Cyberknife tomotherapy allows precision treatment through a robotic arm that delivers multiple angles of radiation to a tumor. The system modulates the radiation dose, minimizing the impact on healthy tissue. Gamma knife has exact doses of radiation to the affected area, reducing damage to healthy brain tissues. MRI Linac allows clinicians to visualize the tumor in real-time during treatment and adapt therapy as needed. Stereotactic advanced electron/cobalt-60 linear accelerators deliver high doses of radiation from multiple angles to treat a small area with pinpoint accuracy, minimizing the impact on surrounding healthy tissues. Particle therapy systems use charged particles to target cancer cells precisely, minimizing the radiation dose to nearby healthy tissue and potentially reducing the risk of side effects. Internal beam radiotherapy/Brachytherapy involves radiation delivery directly into and near the cancer site, providing a high radiation dose while sparing surrounding healthy tissues. It's often the top choice for treating localized cancers such as prostate and cervical cancers. Afterloaders aim to reduce exposure to radiation health professionals, enhancing policies for patient safety and increasing treatment precision. Applicators are designed instruments intended to aid in positioning the radiation sources into the treatment site in a patient's body. Intraoperative radiation therapy (IORT) systems are advanced radiotherapeutic devices used during surgeries for localized cancer treatment. Seeds are tiny devices that encase radioactive materials. When carefully implanted into cancerous tissues, these seeds can deliver radiation directly to the tumor, minimizing damage to nearby healthy tissues.

Iobenguane (I-131) is a type of molecule that is selectively absorbed by certain types of nervous tissues. This unique characteristic makes it an invaluable tool in diagnosing and treating neuroendocrine tumors. Rhenium-186 isotope takes advanced medical science a step further by the exemplary way its gamma radiation properties enable medical professionals to track its effectiveness in patients with medical imaging technology. Samarium-153 has a dual capacity, its beta particles target and destroy cancer cells, its gamma emissions facilitate imaging and tracking its distribution through the body.

Procedure: Increasing advancements in external beam radiotherapy to streamline process and improve patient comfort

External Beam Radiotherapy (EBRT) is the most typical radiotherapy used to treat various cancers. 3D conformal radiotherapy effectively treats many types of cancers and is well-regarded for its precision and ability to minimize side effects. Image-guided Radiotherapy (IGRT) is an advanced form of radiotherapy involving imaging techniques during treatment delivery. Intensity-modulated Radiotherapy (IMRT) allows the radiotherapy beam to be optimized to the tumor's shape, allowing differing degrees of radiation intensity to various parts of the cancer. Particle therapy uniquely uses charged atomic particles, providing a low dose to the tissues they pass through and then depositing their energy at a precise point. Stereotactic therapy allows for high-dose delivery, particularly to small, well-defined tumors in the brain and other sites, while minimizing the radiation to adjacent normal tissues, thus mitigating potential side effects. Instillation radiotherapy involves injecting a radioactive substance directly into a body cavity or the bladder to treat superficial cancers. Brachytherapy is radiotherapy where the radioactive source is placed inside or next to the tumor, ensuring high-dose radiation while sparing healthy tissues. High-dose-rate (HDR) brachytherapy aims to destroy cancer cells while minimizing the exposure and damage to surrounding healthy tissues. LDR brachytherapy has been extensively used for treating numerous types of cancers, including cervical, prostate, and eye cancer. Pulsed-dose-rate (PDR) brachytherapy involves temporally confined radiation delivery cycles where radiation is emitted in pulses, usually once per hour. This technique seeks to maximize the tumor's dose delivery while safeguarding the surrounding healthy tissue. Intravenous Radiotherapy involves administering liquid radioactive substances into the body via a vein. This treatment is typically used for cancers that have spread or metastasized. Oral Radiotherapy involves ingesting radioactive substances through a pill or liquid. Notable for treating conditions such as thyroid cancer. Systemic radiotherapy uses radiopharmaceuticals that circulate throughout the body, ideal for treating cancers that have spread to bones or multiple sites.

Application: Growing application of radiotherapy for gynecological cancer

Radiotherapy plays a substantial role in breast cancer treatment, substantially reducing the reoccurrence risk within the breast area after surgery. Cervical cancer treatment frequently incorporates radiotherapy either alone or combined with chemotherapy. The need for radiotherapy heavily relies on the cancer stage and localization. Radiotherapy for colorectal cancer treatment is used before surgery to shrink the tumor and after the surgery to kill the remaining cells. Radiation therapy is commonly used to treat various types of gynecological cancers. Depending upon the type and stage of the cancer, radiation is used as primary therapy, adjunctive therapy, or palliative therapy. Radiotherapy is crucial in managing head and neck cancers, often in conjunction with surgery and chemotherapy. Radiotherapy for lung cancer serves as a primary mode of treatment. Penile cancer, although rare, often uses radiation therapy as a primary or supplementary treatment. Radiotherapy is very effective in curative treatment of localized prostate cancer. In comparison, radiotherapy is mostly used for gynecological cancer as it results in local control and survival with few complications.

End-User: Significant role of radiotherapy for hospitals service as they provide comprehensive care for cancer patients

Hospitals provide comprehensive care for cancer patients, including diagnostic and therapeutic services. The offering of radiotherapy as an integrated service within the hospital setting allows for better coordination of care, leading to improved patient outcomes. Independent radiotherapy centers are specialized clinics that offer radiation therapy to cancer patients. These centers provide patients with more personalized and convenient care. While these entities may offer a partial range of services, hospitals can often provide radiotherapy treatment more efficiently and patient-centeredly. Hospitals typically have a broader range of services, enabling them to provide holistic care, drawing patients dealing with multiple health issues. On the other hand, independent radiotherapy centers offer a more patient-centric approach, preferred by patients only seeking radiotherapy.

Regional Insights

The adoption of radiotherapy in the Americas is driven by various factors, primarily increasing cancer prevalence rates and a general preference for non-invasive treatment methods. Advanced technologies such as 3D conformal radiotherapy (3D CRT) and intensity-modulated radiotherapy (IMRT) contribute to this market's growth. Simultaneously, government initiatives focusing on cancer prevention and control are a significant factor behind this market's expansion. EMEA region has an increasing need for radiotherapy due to rising cancer incidents. With diverse cancer cases observed across the region, radiotherapy becomes a preferred treatment solution, offering targeted and efficient treatment outcomes. Regulatory approvals for innovative radiotherapy devices, the proliferation of cancer research, and robust healthcare frameworks further bolster the market. The APAC region is witnessing a rapid expansion in the radiotherapy market driven by the escalating burden of cancer. Several countries have high cancer rates, fueling the need for effective treatment modalities, including radiotherapy. The sector's growth is amplified by increasing awareness about early diagnosis, improved access to cancer treatments, and technological advancements within this domain. APAC's emerging economies are also investing heavily in healthcare infrastructure, which further propels the adoption of radiotherapy.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Radiotherapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Radiotherapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Radiotherapy Market, highlighting leading vendors and their innovative profiles. These include Accuray Incorporated, Agilent Technologies Inc., Becton, Dickinson and Company, Cardinal Health, Inc., Charles River Laboratories International, Inc., Elekta AB, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., IBA Dosimetry GmbH, IntraOp Medical, Inc., Koninklijke Philips N.V., Leo Cancer Care, Mevion Medical Systems, Panacea Medical Technologies Pvt. Ltd., PerkinElmer, Inc., Qfix, Quanterix Corporation, Radiology Oncology Systems, Siemens AG, Varian Medical Systems, Inc., ViewRay Technologies, Inc., and ZEISS Group.

Market Segmentation & Coverage

This research report categorizes the Radiotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Hardware
- Software & Service

Type
- External Beam Radiotherapy/Teletherapy
  - Conventional Cabalt-60 Teletherapy Units
  - Linear Accelerators
    - Conventional Linear Accelerators
    - CyberKnife TomoTherapy
    - Gamma Knife
    - MRI LINAC
    - Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators

Particle Therapy Systems
- Cyclotrons
- Synchrocyclotron
- Synchrotrons

Internal Beam Radiotherapy/Brachytherapy
- Afterloaders
- Applicators
- IORT Systems
- Seeds

Systemic Radiotherapy
- lobenguane (l-131)
- Rhenium-186
- Samarium-153

Procedure
- External Beam Radiotherapy
  - 3D Conformal Radiotherapy
  - Image-Guided Radiotherapy
  - Intensity-Modulated Radiotherapy
  - Particle Therapy
  - Stereotactic Therapy

Instillation Radiotherapy
Internal Beam Radiotherapy or Brachytherapy
- High-Dose-Rate Brachytherapy
- Low-Dose-Rate Brachytherapy
- Pulsed-Dose-Rate Brachytherapy

Intravenous Radiotherapy
Oral Radiotherapy
Systemic Radiotherapy

Application
- Breast Cancer
- Cervical Cancer
- Colorectal Cancer
- Gynecological Cancer
- Head & Neck Cancer
- Lung Cancer
- Penile Cancer
- Prostate Cancer

End-User
- Hospitals
- Independent Radiotherapy Centers

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Radiotherapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Radiotherapy Market?

3. What are the technology trends and regulatory frameworks in the Radiotherapy Market?

4. What is the market share of the leading vendors in the Radiotherapy Market?

5. Which modes and strategic moves are suitable for entering the Radiotherapy Market?

Product Code: MRR-42653751E6AE

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing adoption of radiotherapy procedures for cancer treatment
  - 5.1.1.2. Rising preference for minimally invasive procedures
  - 5.1.1.3. Increasing government initiatives and programs for radiotherapy
- 5.1.2. Restraints
  - 5.1.2.1. High treatment costs and limited availability of trained professionals
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancements and improvements in radiotherapy devices
  - 5.1.3.2. Introduction of robotic radiotherapy systems for cancer treatment
- 5.1.4. Challenges
  - 5.1.4.1. Risks associated with radiation exposure
5.2. Market Segmentation Analysis
- 5.2.1. Product: Advancements in hardware manufacturing process as it provide high radiation doses to the tumor site
- 5.2.2. Type: Consumer preference for external beam radiotherapy/teletherapy as they target tumor from outside and large tumors
- 5.2.3. Procedure: Increasing advancements in external beam radiotherapy to streamline process and improve patient comfort
- 5.2.4. Application: Growing application of radiotherapy for gynecological cancer
- 5.2.5. End-User: Significant role of radiotherapy for hospitals service as they provide comprehensive care for cancer patients
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Radiotherapy Market, by Product

6.1. Introduction
6.2. Hardware
6.3. Software & Service

7. Radiotherapy Market, by Type

7.1. Introduction
7.2. External Beam Radiotherapy/Teletherapy
7.3. Internal Beam Radiotherapy/Brachytherapy
7.4. Systemic Radiotherapy

8. Radiotherapy Market, by Procedure

8.1. Introduction
8.2. External Beam Radiotherapy
8.3. Instillation Radiotherapy
8.4. Internal Beam Radiotherapy or Brachytherapy
8.5. Intravenous Radiotherapy
8.6. Oral Radiotherapy
8.7. Systemic Radiotherapy

9. Radiotherapy Market, by Application

9.1. Introduction
9.2. Breast Cancer
9.3. Cervical Cancer
9.4. Colorectal Cancer
9.5. Gynecological Cancer
9.6. Head & Neck Cancer
9.7. Lung Cancer
9.8. Penile Cancer
9.9. Prostate Cancer

10. Radiotherapy Market, by End-User

10.1. Introduction
10.2. Hospitals
10.3. Independent Radiotherapy Centers

11. Americas Radiotherapy Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Radiotherapy Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Radiotherapy Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. CIVCO Radiotherapy and Qfix Launch CQ Medical Brand
- 14.3.2. GE HealthCare Collaborates with Elekta to Expand Access to Precision Radiation Therapy Solutions in India
- 14.3.3. IBA Launches Latest Radiation Therapy Quality Assurance Offerings
14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio